Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01242514
Other study ID # D4300C00005
Secondary ID 2010-020892-22
Status Terminated
Phase Phase 3
First received November 10, 2010
Last updated February 25, 2014
Start date January 2011
Est. completion date January 2015

Study information

Verified date February 2014
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Canada: Health CanadaUnited States: Food and Drug AdministrationBelgium: Federal Agency for Medicinal Products and Health ProductsBulgaria: Bulgarian Drug AgencyCzech Republic: State Institute for Drug ControlEstonia: The State Agency of MedicineFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesHungary: National Institute of PharmacyIsrael: Ministry of HealthLatvia: State Agency of MedicinesLithuania: State Medicine Control Agency - Ministry of HealthPoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsPortugal: National Pharmacy and Medicines InstituteRomania: National Medicines AgencySerbia and Montenegro: Agency for Drugs and Medicinal DevicesSlovakia: State Institute for Drug ControlSpain: Agencia Española de Medicamentos y Productos SanitariosUkraine: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyAustralia: Department of Health and Ageing Therapeutic Goods AdministrationIndia: Drugs Controller General of IndiaArgentina: National Administration of Drugs, Food & Medical Technology (ANMAT)Brazil: National Health Surveillance AgencyChile: Instituto de Salud Pública de ChileMexico: Federal Commission for Sanitary Risks ProtectionPeru: General Directorate of Pharmaceuticals, Devices, and DrugsSouth Africa: Medicines Control Council
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).


Recruitment information / eligibility

Status Terminated
Enrollment 1917
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients who have successfully completed a qualifying study (D4300C00001, D4300C00002, D4300C00003 or D4300C00004) with fostamatinib

- Patients who have participated in a qualifying study and who have been classified as non-responders due to pre-defined lack of efficacy at Week 12 (D4300C00001, D4300C00002, D4300C00003).

Exclusion Criteria:

- Premature withdrawal from the qualifying study (D4300C00001, D4300C00002, D4300C00003 and D4300C00004)

- Females who are pregnant or breast feeding

- Poorly controlled hypertension

- Significant liver function test abnormalities or physical symptoms of hepatotoxicity

- Significant infection

- Gastrointestinal intolerance

- Cancer

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fostamatinib
Fostamatinib 100mg twice daily
Fostamatinib
Fostamatinib 150mg once daily
Fostamatinib
Fostamatinib 100mg once daily

Locations

Country Name City State
Argentina Research Site Buenos Aires Caba
Argentina Research Site Caba Buenos Aires
Argentina Research Site Ciudad Autonoma Bs As
Argentina Research Site Ciudad Autonoma Bs As CBA
Argentina Research Site Ciudad de Buenos Aires
Argentina Research Site Cordoba CRD
Argentina Research Site Quilmes
Argentina Research Site Rosario Santa Fe
Argentina Research Site San Juan
Argentina Research Site San Miguel de Tucuman TUC
Australia Research Site Cairns
Australia Research Site Camperdown New South Wales
Australia Research Site Southport Queensland
Belgium Research Site Brussels
Belgium Research Site Gent
Belgium Research Site Gilly
Belgium Research Site Liege
Belgium Research Site Yvoir
Brazil Research Site Curitiba PR
Brazil Research Site Goiania GO
Brazil Research Site Recife PE
Brazil Research Site Rio de Janeiro
Brazil Research Site Sao Paulo SP
Bulgaria Research Site Pleven
Bulgaria Research Site Plovdiv
Bulgaria Research Site Sevlievo
Bulgaria Research Site Sofia
Canada Research Site Bowmanville Ontario
Canada Research Site Edmonton Alberta
Canada Research Site Etobicoke Ontario
Canada Research Site Hamilton Ontario
Canada Research Site Mississauga Ontario
Canada Research Site Montreal Quebec
Canada Research Site Ottawa Ontario
Canada Research Site Pointe-claire Quebec
Canada Research Site Quebec City Quebec
Canada Research Site Rimouski Quebec
Canada Research Site St John's Newfoundland and Labrador
Canada Research Site St. John's Newfoundland and Labrador
Canada Research Site Toronto Ontario
Canada Research Site Trois-rivieres Quebec
Canada Research Site Victoria British Columbia
Canada Research Site Winnipeg Manitoba
Chile Research Site Osorno X Region
Chile Research Site Santiago
Colombia Research Site Barranquilla Atlantico
Colombia Research Site Bogota Cundinamarca
Colombia Research Site Bucaramanga Santander
Czech Republic Research Site Brno
Czech Republic Research Site Bruntal
Czech Republic Research Site Ceska Lipa
Czech Republic Research Site Ceske Budejovice
Czech Republic Research Site Hlucin
Czech Republic Research Site Hostivice
Czech Republic Research Site Kladno
Czech Republic Research Site Liberec
Czech Republic Research Site Ostrava
Czech Republic Research Site Ostrava - Trebovice
Czech Republic Research Site Praha
Czech Republic Research Site Sokolov
Czech Republic Research Site Terezin
Czech Republic Research Site Zlin
Estonia Research Site Parnu
Estonia Research Site Tallinn
Estonia Research Site Tartu
France Research Site Orleans Cedex 1
Germany Research Site Aachen Nordrhein Westfalen
Germany Research Site Erlangen
Germany Research Site Frankfurt
Germany Research Site Halle Sachsen
Germany Research Site Hamburg
Germany Research Site Heidelberg
Germany Research Site Herne
Germany Research Site Koln
Germany Research Site Leipzig
Germany Research Site Muenchen
Hungary Research Site Balatonfured
Hungary Research Site Bekescsaba
Hungary Research Site Budapest
Hungary Research Site Debrecen
Hungary Research Site Mako
Hungary Research Site Sopron
Hungary Research Site Szentes
Hungary Research Site Zalaegerszeg-pozva
India Research Site Ahmedabad Gujarat
India Research Site Bangalore Karnataka
India Research Site Coimbatore Tamil Nadu
India Research Site Gandhinagar Gujarat
India Research Site Hyderabad Andhra Pradesh
India Research Site Lucknow Uttar Pradesh
India Research Site Madurai Tamil Nadu
India Research Site Mangalore Karnataka
India Research Site Mumbai Maharashtra
India Research Site Nagpur Maharshtra
India Research Site Pune Maharashtra
India Research Site Secunderabad Andhra Pradesh
India Research Site Udupi Karnataka
India Research Site Vadodara Gujarat
Israel Research Site Ashkelon
Israel Research Site Haifa
Israel Research Site Kfar-saba
Israel Research Site Ramat-gan
Israel Research Site Rehovot
Italy Research Site Jesi AN
Italy Research Site Udine UD
Italy Research Site Varese VA
Latvia Research Site Liepaja
Latvia Research Site Riga
Latvia Research Site Valmiera
Lithuania Research Site Kaunas
Lithuania Research Site Klaipeda
Lithuania Research Site Siauliai
Mexico Research Site Chihuahua
Mexico Research Site Guadalajara JAL
Mexico Research Site Mexicali Baja California
Mexico Research Site Mexico Distrito Federal
Mexico Research Site Monterrey NL
Mexico Research Site Obrergon SON
Mexico Research Site Saltillo Coahuila
Mexico Research Site San Luis Potosi
Peru Research Site Arequipa
Peru Research Site Lima
Peru Research Site Pueblo Libre Lima
Peru Research Site San Borja Lima
Peru Research Site San Isidro Lima
Poland Research Site Bytom
Poland Research Site Chelm Slaski
Poland Research Site Grodzisk Mazowiecki
Poland Research Site Kalisz
Poland Research Site Katowice
Poland Research Site Krakow
Poland Research Site Lodz
Poland Research Site Warszawa
Poland Research Site Wroclaw
Poland Research Site Zyrardow
Portugal Research Site Aveiro
Portugal Research Site Coimbra
Portugal Research Site Lisboa
Portugal Research Site Porto
Romania Research Site Braila
Romania Research Site Ploiesti Prahova
Russian Federation Research Site Moscow
Russian Federation Research Site Nizhniy Novgorod
Russian Federation Research Site Petrozavodsk
Russian Federation Research Site Ryazan
Russian Federation Research Site Sankt-peterburg
Russian Federation Research Site Voronezh
Russian Federation Research Site Yaroslavl
Serbia Research Site Belgrade
Serbia Research Site Kragujevac
Serbia Research Site Niska Banja
Serbia Research Site Novi Sad
Slovakia Research Site Bratislava
Slovakia Research Site Poprad
Slovakia Research Site Rimavska Sobota
Slovakia Research Site Ruzomberok
Slovakia Research Site Trnava
Slovakia Research Site Zilina
South Africa Research Site Cape Town Western Cape
South Africa Research Site Durban Kwazulu Natal
South Africa Research Site Kempron Park Gauteng
South Africa Research Site Panorama Cape Town
South Africa Research Site Port Elizabeth E Cape
South Africa Research Site Pretoria Gauteng
South Africa Research Site Stellenbosch
Spain Research Site Barcelona
Spain Research Site Merida Extremadura
Ukraine Research Site Donetsk
Ukraine Research Site Ivano-frankivsk
Ukraine Research Site Kharkiv
Ukraine Research Site Kyiv
Ukraine Research Site Lugansk
Ukraine Research Site Lutsk
Ukraine Research Site Lviv
Ukraine Research Site Odessa
Ukraine Research Site Simferopol
Ukraine Research Site Vinnytsia
Ukraine Research Site Vinnytsya
Ukraine Research Site Zaporizhzhya
Ukraine Research Site Zaporyzhzhya
United Kingdom Research Site Basingstoke
United Kingdom Research Site Bracknell Berkshire
United Kingdom Research Site Cambridge
United Kingdom Research Site Christchurch
United Kingdom Research Site Eastbourne Sussex
United Kingdom Research Site Ipswich
United Kingdom Research Site London Greater London
United Kingdom Research Site Maidstone Kent
United Kingdom Research Site Nottingham
United Kingdom Research Site Solihull West Midlands
United Kingdom Research Site Stoke on Trent
United Kingdom Research Site Warrington Cheshire
United Kingdom Research Site Westcliff-on-the Sea
United Kingdom Research Site Wirral
United States Research Site Albany New York
United States Research Site Albuquerque New Mexico
United States Research Site Amarillo Texas
United States Research Site Anaheim California
United States Research Site Anniston Alabama
United States Research Site Asheville North Carolina
United States Research Site Atlanta Georgia
United States Research Site Austin Texas
United States Research Site Birmingham Alabama
United States Research Site Boca Raton Florida
United States Research Site Boston Massachusetts
United States Research Site Bowling Green Kentucky
United States Research Site Brandon Florida
United States Research Site Bridgeport Connecticut
United States Research Site Brooklyn New York
United States Research Site Canton Georgia
United States Research Site Cedar Rapids Iowa
United States Research Site Charleston South Carolina
United States Research Site Charlotte North Carolina
United States Research Site Chesapeake Virginia
United States Research Site Chicago Illinois
United States Research Site Colorado Springs Colorado
United States Research Site Cooperstown New York
United States Research Site Cumberland Maryland
United States Research Site Dallas Texas
United States Research Site Danbury Connecticut
United States Research Site Dayton Ohio
United States Research Site Daytona Beach Florida
United States Research Site Decatur Georgia
United States Research Site Duncansville Pennsylvania
United States Research Site Durham North Carolina
United States Research Site Eagan Minnesota
United States Research Site Elizabethtown Kentucky
United States Research Site Erie Pennsylvania
United States Research Site Fall River Massachusetts
United States Research Site Florissant Missouri
United States Research Site Flowood Mississippi
United States Research Site Fountain Valley California
United States Research Site Frederick Maryland
United States Research Site Freehold New Jersey
United States Research Site Ft. Lauderdale Florida
United States Research Site Glendale Arizona
United States Research Site Greensboro North Carolina
United States Research Site Greenville South Carolina
United States Research Site Hagerstown Maryland
United States Research Site Hixson Tennessee
United States Research Site Hot Springs Arkansas
United States Research Site Houston Texas
United States Research Site Huntington Beach California
United States Research Site Huntsville Alabama
United States Research Site Idaho Falls Idaho
United States Research Site Indianapolis Indiana
United States Research Site Jackson Tennessee
United States Research Site Jacksonville Florida
United States Research Site Kalamazoo Michigan
United States Research Site Kalispell Montana
United States Research Site Katy Texas
United States Research Site Knoxville Tennessee
United States Research Site La Jolla California
United States Research Site Lake Oswego Oregon
United States Research Site Lansing Michigan
United States Research Site Las Cruces New Mexico
United States Research Site Las Vegas Nevada
United States Research Site Lawrenceville Georgia
United States Research Site Lewes Delaware
United States Research Site Long Beach California
United States Research Site Lubbock Texas
United States Research Site Macon Georgia
United States Research Site Marietta Georgia
United States Research Site Mayfield Village Ohio
United States Research Site Memphis Tennessee
United States Research Site Mesa Arizona
United States Research Site Mesquite Texas
United States Research Site Miami Florida
United States Research Site Nashville Tennessee
United States Research Site Nassau Bay Texas
United States Research Site Ocala Florida
United States Research Site Oklahoma City Oklahoma
United States Research Site Olean New York
United States Research Site Omaha Nebraska
United States Research Site Orangeburg South Carolina
United States Research Site Orlando Florida
United States Research Site Oxon Hill Maryland
United States Research Site Palm Harbor Florida
United States Research Site Palo Alto California
United States Research Site Perrysburg Ohio
United States Research Site Philadelphia Pennsylvania
United States Research Site Phoenix Arizona
United States Research Site Pinellas Park Florida
United States Research Site Rapid City South Dakota
United States Research Site Research Triangle Park North Carolina
United States Research Site Richmond Heights Missouri
United States Research Site Roseville California
United States Research Site Roslyn New York
United States Research Site San Antonio Texas
United States Research Site Santa Maria California
United States Research Site Santa Monica California
United States Research Site Scottsdale Arizona
United States Research Site Smithtown New York
United States Research Site South Bend Indiana
United States Research Site St. Clair Shores Michigan
United States Research Site St. Louis Missouri
United States Research Site Syracuse New York
United States Research Site Tacoma Washington
United States Research Site Tampa Florida
United States Research Site Tavares Florida
United States Research Site Torrance California
United States Research Site Trumbull Connecticut
United States Research Site Tucson Arizona
United States Research Site Tuscaloosa Alabama
United States Research Site Upland California
United States Research Site Venice Florida
United States Research Site Waxford Pennsylvania
United States Research Site West Reading Pennsylvania
United States Research Site Worcester Massachusetts
United States Research Site Zephyr Hills Florida

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  Colombia,  Czech Republic,  Estonia,  France,  Germany,  Hungary,  India,  Israel,  Italy,  Latvia,  Lithuania,  Mexico,  Peru,  Poland,  Portugal,  Romania,  Russian Federation,  Serbia,  Slovakia,  South Africa,  Spain,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients Who Had at Least 1 Adverse Event in Any Category AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event Entry in extension to end of study (variable duration; maximum 109 weeks) Yes
Secondary Mean DAS28-CRP Score DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, CRP = C-reactive protein, qd = once daily Weeks 0, 12, 24, 36 and 52 No
Secondary Mean mTSS Score mTSS: modified total sharp score, a measure of structural progression based upon X-rays. Hand and foot joints are scored for erosions and joint space narrowing and the results summed to give a value between 0 and 488. A higher value represents more serious progression of the disease. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, N/A = not applicable, qd = once daily Weeks 0 and 52 No
Secondary Mean HAQ-DI Score HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is then calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, qd = once daily Weeks 0, 12, 24, 36 and 52 No
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4